Long-acting xRNA for Durable, Combination Peptide Therapy in Chronic Metabolic Disease
1:00 pm - Friday 19th February 2027
- The modality: xRNA, a chemically modified long-acting RNA encoding protein and peptides, with durability designed in rather than added by the dosing schedule
- Durability: single-dose expression sustained for weeks; in NHP, peptide and RNA still present at ~25 days, pointing to a dosing interval of around a month
- Combination by design: multiple single-payload xRNA molecules combined at a defined, adjustable ratio and delivered as one product
- Preclinical efficacy: the four-molecule multi-agonist improved weight, glucose and liver function in obesity and MASH models, beating single and triple agonists and, weekly, daily semaglutide
- Takeaway: long-acting xRNA turns encoded peptides into durable, combination cardio-metabolic therapies
